BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33095662)

  • 1. Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium + olodaterol.
    Criner G; Duffy S
    Curr Med Res Opin; 2021 Feb; 37(2):275-284. PubMed ID: 33095662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
    Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
    Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.
    Hoogendoorn M; Corro Ramos I; Soulard S; Cook J; Soini E; Paulsson E; Rutten-van Mölken M
    BMJ Open; 2021 Aug; 11(8):e049675. PubMed ID: 34348953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
    Quint JK; Montonen J; Esposito DB; He X; Koerner L; Wallace L; de la Hoz A; Miravitlles M
    Adv Ther; 2021 May; 38(5):2249-2270. PubMed ID: 33721209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study.
    Valipour A; Avdeev S; Barczyk A; Bayer V; Fridlender Z; Georgieva M; Kudela O; Medvedchikov A; Miron R; Sanzharovskaya M; Šileikienė V; Šorli J; Spielmanns M; Szalai Z
    Int J Chron Obstruct Pulmon Dis; 2021; 16():615-628. PubMed ID: 33731991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT
    Buhl R; Dreher M; Korn S; Taube C; Stock C; Zehendner CM; Kondla A; Vogelmeier CF
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2601-2608. PubMed ID: 33122898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score-matched cohort analysis.
    Muro S; Suzuki M; Nakamura S; Wang JR; Garry EM; Sakamoto W; de Souza S
    Respir Res; 2021 Jun; 22(1):180. PubMed ID: 34140019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.
    Hoogendoorn M; Corro Ramos I; Baldwin M; Luciani L; Fabron C; Detournay B; Rutten-van Mölken MPMH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():447-456. PubMed ID: 30863045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO
    Rabe KF; Chalmers JD; Miravitlles M; Kocks JWH; Tsiligianni I; de la Hoz A; Xue W; Singh D; Ferguson GT; Wedzicha J
    Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy.
    Calverley PMA; Hoz A; Xue W; Ferguson GT; Miravitlles M
    COPD; 2020 Oct; 17(5):477-484. PubMed ID: 32928003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
    Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Spiolto Respimat® : tiotropium-olodaterol fixed combination for therapy of chronic obstructive pulmonary disease (COPD)].
    Cataldo D
    Rev Med Liege; 2016 Jun; 71(6):308-313. PubMed ID: 28383865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.
    Muruganandan S; Jayaram L
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1179-89. PubMed ID: 26124657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
    Calverley PMA; Anzueto AR; Carter K; Grönke L; Hallmann C; Jenkins C; Wedzicha J; Rabe KF
    Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses.
    Maltais F; de la Hoz A; Casaburi R; O'Donnell D
    Adv Ther; 2021 Feb; 38(2):835-853. PubMed ID: 33306188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.
    Calzetta L; Matera MG; Cazzola M; Rogliani P
    Adv Ther; 2019 Dec; 36(12):3291-3298. PubMed ID: 31654332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Rogliani P; Ora J; Matera MG
    Expert Rev Clin Pharmacol; 2015; 8(5):529-39. PubMed ID: 26294073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiotropium/Olodaterol: A Review in COPD.
    Dhillon S
    Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.